

CASE No. CL/V-31855A/CVA

REMARKS***Remaining Claims***


Claim 5 has been amended to more clearly point out and distinctly claim the invention. In response to a voice message from the Examiner, claims 15-17 have been cancelled through this Amendment without prejudice to filing a divisional application containing the same. After these amendments are entered, nine (9) claims (Claims 4-10 and 11-12) remain pending in this application through this Amendment.

Claim objections

The objection of Claim 5 has been overcome by the amendments of claim 5.

Should the Examiner believe that a discussion with Applicants' representative would further the prosecution of this application, the Examiner is respectfully invited to contact the undersigned. Please address all correspondence to Thomas Hoxie, Novartis Corporation, Corporate Intellectual Property, One Health Plaza, Bldg. 430, East Hanover, NJ 07936-1080. The Commissioner is hereby authorized to charge any other fees which may be required under 37 C.F.R. §§1.16 and 1.17, or credit any overpayment, to Deposit Account No. 19-0134.

Respectfully submitted,



Jian S. Zhou
Reg. No. 41,422
(678) 415-4691

Date:

10/10/2003

Novartis Corporation
Corporate Intellectual Property
One Health Plaza, Bldg. 430
East Hanover, NJ 07936-1080